BIOMAT Database Logo BIOMAT Database Logo

Plasma concentrations of fibrinopeptide A, fibrinogen fragment B beta 1-42 and beta-thromboglobulin following total hip replacement. 1982

D A Lane, and H Ireland, and S Wolff, and R Grant, and S Jennings, and T Allen-Mersh

Plasma concentrations of thrombin sensitive peptide fibrinopeptide A (FpA), plasmin sensitive fibrinogen fragment B beta 1-42 and the platelet release product beta-thromboglobulin (beta TG) have been measured in 36 patients before and after total hip replacement. Statistically significant elevations of all three activation products were observed in the days following operation. There were small differences in plasma concentrations of FpA, B beta 1-42 and beta TG in patients who did (n = 13) and did not (n = 23) develop post operative deep vein thrombosis, as assessed by ascending venography on post operative day 10, but these differences were not statistically significant. It is concluded that coagulation and fibrinolytic systems and also blood platelets are activated following total hip replacement operations. However, the formation of post operative deep vein thrombosis can not be effectively monitored by measurement of the activation products.

UI MeSH Term Description Entries
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011300 Preoperative Care Care given during the period prior to undergoing surgery when psychological and physical preparations are made according to the special needs of the individual patient. This period spans the time between admission to the hospital to the time the surgery begins. (From Dictionary of Health Services Management, 2d ed) Care, Preoperative,Preoperative Procedure,Preoperative Procedures,Procedure, Preoperative,Procedures, Preoperative
D005338 Fibrin Fibrinogen Degradation Products Soluble protein fragments formed by the proteolytic action of plasmin on fibrin or fibrinogen. FDP and their complexes profoundly impair the hemostatic process and are a major cause of hemorrhage in intravascular coagulation and fibrinolysis. Antithrombin VI,Fibrin Degradation Product,Fibrin Degradation Products,Fibrin Fibrinogen Split Products,Degradation Product, Fibrin,Degradation Products, Fibrin,Product, Fibrin Degradation
D005340 Fibrinogen Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products. Coagulation Factor I,Factor I,Blood Coagulation Factor I,gamma-Fibrinogen,Factor I, Coagulation,gamma Fibrinogen
D005344 Fibrinopeptide A Two small peptide chains removed from the N-terminal segment of the alpha chains of fibrinogen by the action of thrombin during the blood coagulation process. Each peptide chain contains 18 amino acid residues. In vivo, fibrinopeptide A is used as a marker to determine the rate of conversion of fibrinogen to fibrin by thrombin. Fibrinopeptides A
D006622 Hip Prosthesis Replacement for a hip joint. Femoral Head Prosthesis,Femoral Head Prostheses,Hip Prostheses,Prostheses, Femoral Head,Prostheses, Hip,Prosthesis, Femoral Head,Prosthesis, Hip
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D001609 Beta-Globulins Serum proteins with an electrophoretic mobility that falls between ALPHA-GLOBULINS and GAMMA-GLOBULINS. Beta(1)CA Globulin,Beta-Globulin,Beta Globulin,Beta Globulins

Related Publications

D A Lane, and H Ireland, and S Wolff, and R Grant, and S Jennings, and T Allen-Mersh
Plasma concentrations of fibrinopeptide A and fibrinopeptide B beta 15-42 in glomerulonephritis and the nephrotic syndrome.
June 1985, Archives of internal medicine,
D A Lane, and H Ireland, and S Wolff, and R Grant, and S Jennings, and T Allen-Mersh
[Fibrinopeptide A, fibrinopeptide B beta 15-42].
September 1999, Nihon rinsho. Japanese journal of clinical medicine,
D A Lane, and H Ireland, and S Wolff, and R Grant, and S Jennings, and T Allen-Mersh
Plasma beta-thromboglobulin, fibrinopeptide A and B beta 15-42 antigen in relation to postoperative DVT, malignancy and stanozolol treatment.
April 1985, Thrombosis and haemostasis,
D A Lane, and H Ireland, and S Wolff, and R Grant, and S Jennings, and T Allen-Mersh
[Fibrinopeptide A (FPA) and fibrinopeptide B beta 15-42 (FPB beta 15-42)].
March 1995, Nihon rinsho. Japanese journal of clinical medicine,
D A Lane, and H Ireland, and S Wolff, and R Grant, and S Jennings, and T Allen-Mersh
[Plasma fibrinopeptide A and fibrinopeptide B beta 15-42 levels in patients with Behçet's disease].
June 1986, Nippon Ganka Gakkai zasshi,
D A Lane, and H Ireland, and S Wolff, and R Grant, and S Jennings, and T Allen-Mersh
Plasma fibrinopeptide A and beta-thromboglobulin in major bacterial infections.
December 1982, Thrombosis and haemostasis,
D A Lane, and H Ireland, and S Wolff, and R Grant, and S Jennings, and T Allen-Mersh
[FPA (fibrinopeptide A) and B beta 15-42)].
April 1987, Rinsho byori. The Japanese journal of clinical pathology,
D A Lane, and H Ireland, and S Wolff, and R Grant, and S Jennings, and T Allen-Mersh
[Molecular markers of hemostatic mechanisms--fibrinopeptide B beta 1-42].
March 1989, Rinsho byori. The Japanese journal of clinical pathology,
D A Lane, and H Ireland, and S Wolff, and R Grant, and S Jennings, and T Allen-Mersh
Plasma fibrinopeptide A and beta-thromboglobulin in patients with chest pain.
August 1983, Thrombosis and haemostasis,
D A Lane, and H Ireland, and S Wolff, and R Grant, and S Jennings, and T Allen-Mersh
[Molecular markers of hemostatic mechanisms--fibrinopeptide A and fibrinopeptide B beta 15-42].
March 1989, Rinsho byori. The Japanese journal of clinical pathology,
Copied contents to your clipboard!